TLRY Stock News: Tilray Inc looks to bounce back from last week’s massive sell-off

NASDAQ:TLRY dropped by a further 9.83% on Friday to close out a devastating week for the stock.
A glaring analyst warning and downgrade has scared retail investors off of the stock.
Tilray’s upcoming earnings call should shed some light on its reported merger with Aphria.

NASDAQ:TLRY investors experienced the whole spectrum of emotions as the Canadian cannabis giant skyrocketed to a 52-week high of $67.00 on Wednesday before rapidly deflating to finish the week at $29.00. The three-day drop represented 56% drop in the stock’s value and the sudden surge has dramatically placed the 50-day and 200-day moving averages out of sorts. Until the recent spike in price, Tilray had been trading in the low single digits for the better part of 2020 and hadn’t seen double digits since before the market crash in March.

One of the catalysts for Tilray’s sudden plunge was the harsh assessment by GLJ Research analyst Gordon Johnson. Regarding Tilray’s prospects, Johnson was not shy about his negative outlook stating that a $0 price forecast is very much a realistic outcome in the short-term. Johnson called Tilray’s future past 2022 “dismal”, and encouraged investors to sell their shares as quickly as possible. Johnson’s harsh analysis of Tilray added to the downward momentum the stock was already experiencing since Wednesday.

TLRY stock chart

It’s not all negative news for Tilray, as its upcoming merger with Aphria (NASDAQ:APHA) should help to stave off any sort of imminent danger of bankruptcy. Tilray has also continued to advance its reach across Europe, with recent deals to supply medical marijuana to Portugal and the United Kingdom, more markets should be on the way in the near future. Despite all of these prospects, it is often difficult for investors to ignore a negative forecast like the one that was provided by Johnson, so shareholders may continue to experience short-term pain, at least until Tilray’s earnings call on February 17th.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.